Incretin‐based therapies for the management of cardiometabolic ...

Incretin-based therapies for the management of cardiometabolic ...

Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are incretin-based ...

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight ...

Achieving equitable access to incretin-based therapies in ... - NCBI

The role of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP1RAs) and dual GLP-1/glucose-dependent insulinotropic ...

Incretin-based therapies for the management of cardiometabolic ...

Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) are incretin‐based ...

Incretin-based therapies for the treatment of obesity-related diseases

Incretin-based therapies have been associated with a body weight (BW) reduction of ≥5% in at least half of patients in most randomized ...

Cardiovascular Effects of Incretin-Based Therapies

GLP-1 receptor agonists (GLP-1Ras) and dipeptidyl peptidase 4 inhibitors (DPP-4is) represent two drug classes used for the treatment of type 2 ...

Cardiovascular Actions of Incretin-Based Therapies - AHA Journals

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 distinct classes of ...

Cardiovascular Outcomes Trials of Incretin-Based Therapies

Cardiovascular Outcomes Trials of Incretin-Based Therapies ... The cardiovascular (CV) safety of glucagon-like peptide 1 (GLP-1) receptor agonists ...

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to ...

Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of their efficacy, ...

Incretin-based therapy: a powerful and promising weapon in the ...

Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agonists, are able to successfully counteract several of the ...

Incretins-Based Therapies and Their Cardiovascular Effects - MDPI

About GLP-1RA, exenatide reduces thrombin, ADP, and collagen-induced platelet aggregation in human megakaryocyte cell lines. Moreover, treatment with this drug ...

Clinical Application of Incretin-Based Therapy: Therapeutic Potential ...

Incretin-based therapies have recently been introduced into clinical practice and are currently the newest class of glucose-lowering agents available for the ...

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to ...

Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of ...

The role of incretin receptor agonists in the treatment of obesity - Forst

The development of the glucagon-like peptide-1 receptor agonists for chronic weight management has triggered new interest in the incretins and ...

Effect of Long-term Incretin-Based Therapies on Ischemic Heart ...

Patients with type 2 diabetes mellitus (T2DM) experience many cardiovascular complications. Several studies have demonstrated the ...

Incretin-Based Therapies for Diabetic Complications - MDPI

Incretin-based therapies such as dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) are now widely used in the ...

Incretin‐based therapies for the management of cardiometabolic ...

Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future · Medicinal Research Reviews, ...

Comparison of efficacy between incretin-based therapies for type 2 ...

Incretin based therapies are available as either incretin mimetics (also called GLP-1 agonists) or incretin enhancers (DPP-4 inhibitors).

Incretin-based therapy of metabolic disease | Ugeskriftet.dk

Release from the gut of incretin hormones (GIP and GLP-1) is responsible for amplification of insulin secretion, which occurs when nutrients are ...

New incretins poised to improve clinical care and cardiometabolic ...

“Type 2 diabetes patients remain in poor glycemic control for more than seven years before intensification of treatment.” Repeated studies have ...